Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.

Neukam K, Caruz A, Rivero-Juárez A, Barreiro P, Merino D, Real LM, Herrero R, Camacho A, Soriano V, Di Lello FA, Macías J, Rivero A, Pineda JA.

AIDS. 2013 Nov 13;27(17):2715-24. doi: 10.1097/01.aids.0000432459.36970.a9.

PMID:
23842134
2.

Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.

Di Lello FA, Caruz A, Rallon NI, Rivero-Juarez A, Neukam K, Barreiro P, Camacho A, García-Rey S, Rivero A, Soriano V, Cifuentes C, Macias J, Pineda JA.

Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1427-35. doi: 10.1007/s10096-013-1894-9. Epub 2013 May 29.

PMID:
23715768
3.

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.

Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A.

J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11.

PMID:
21990051
4.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

Rivero-Juarez A, Camacho A, Caruz A, Neukam K, Gonzalez R, Di Lello FA, Perez-Camacho I, Mesa P, Torre-Cisneros J, Peña J, Pineda JA, Rivero A.

AIDS. 2012 May 15;26(8):1009-15. doi: 10.1097/QAD.0b013e3283528b1c.

PMID:
22382144
5.

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, Rivero-juárez A, Macías J, Gómez-Mateos J, Rivero A.

AIDS. 2011 Jul 17;25(11):1415-20. doi: 10.1097/QAD.0b013e328348a7ac.

PMID:
21572301
6.

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.

Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C.

J Viral Hepat. 2012 Sep;19(9):615-22. doi: 10.1111/j.1365-2893.2011.01584.x. Epub 2012 Feb 9.

PMID:
22863265
7.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
8.

Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(6):1059-67. doi: 10.3851/IMP2322. Epub 2012 Aug 17.

PMID:
22898703
9.

The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

Mandorfer M, Neukam K, Reiberger T, Payer BA, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Meyer-Olson D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M.

AIDS. 2013 Nov 13;27(17):2707-14. doi: 10.1097/01.aids.0000432460.44593.ef.

PMID:
23835502
10.

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.

Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K.

J Viral Hepat. 2011 Oct;18(10):e550-60. doi: 10.1111/j.1365-2893.2011.01468.x. Epub 2011 May 23.

PMID:
21914076
11.

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.

de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA.

PLoS One. 2012;7(2):e31016. doi: 10.1371/journal.pone.0031016. Epub 2012 Feb 6.

12.

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.

Neukam K, Almeida C, Caruz A, Rivero-Juárez A, Rallón NI, Di Lello FA, Herrero R, Camacho A, Benito JM, Macías J, Rivero A, Soriano V, Pineda JA.

J Antimicrob Chemother. 2013 Apr;68(4):915-21. doi: 10.1093/jac/dks488. Epub 2012 Dec 12.

PMID:
23243129
13.

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N.

Ann Hepatol. 2012 Nov-Dec;11(6):876-81.

14.

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.

J Gastroenterol. 2012 Oct;47(10):1143-51. doi: 10.1007/s00535-012-0578-z. Epub 2012 Mar 24.

PMID:
22441534
15.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
16.

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Clark PJ, Thompson AJ, Zhu M, Vock DM, Zhu Q, Ge D, Patel K, Harrison SA, Urban TJ, Naggie S, Fellay J, Tillmann HL, Shianna K, Noviello S, Pedicone LD, Esteban R, Kwo P, Sulkowski MS, Afdhal N, Albrecht JK, Goldstein DB, McHutchison JG, Muir AJ; IDEAL investigators.

J Viral Hepat. 2012 May;19(5):332-40. doi: 10.1111/j.1365-2893.2011.01553.x. Epub 2012 Feb 22.

17.

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.

Toyoda H, Kumada T, Tada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F.

J Med Virol. 2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.

PMID:
22095536
18.

Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Rallón NI, Soriano V, Naggie S, Restrepo C, McHutchison J, Vispo E, Benito JM.

J Antimicrob Chemother. 2012 May;67(5):1246-9. doi: 10.1093/jac/dkr598. Epub 2012 Feb 1.

19.

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.

Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N.

Hepatology. 2012 Nov;56(5):1611-21. doi: 10.1002/hep.25826.

PMID:
22577043
20.

IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M, Takahashi S, Ochi H, Hayes CN, Tanaka S, Arihiro K, Chayama K.

J Gastroenterol. 2012 Jul;47(7):834-44. doi: 10.1007/s00535-012-0550-y. Epub 2012 Feb 18.

PMID:
22350701

Supplemental Content

Support Center